
Athenex ATNX
Annual report 2022
added 03-20-2023
Athenex General and Administrative Expenses 2011-2026 | ATNX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Athenex
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.9 M | 64.2 M | 96.9 M | 66.7 M | 49 M | 46.1 M | 26 M | 27 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 96.9 M | 26 M | 52.6 M |
Quarterly General and Administrative Expenses Athenex
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 9.44 M | - | 14.9 M | - | 18.1 M | 21.2 M | 20.7 M | 31.4 M | 22.2 M | 17.5 M | 25.7 M | 18.1 M | 16.3 M | 17.2 M | 15.2 M | 11.6 M | 11.5 M | 12.8 M | 13.1 M | 12.3 M | 10.4 M | 13.6 M | 9.8 M | 10.3 M | 6.79 M | 4.57 M | 4.34 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 31.4 M | 4.34 M | 14.8 M |
General and Administrative Expenses of other stocks in the Drug manufacturers industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
7.48 M | - | 7.5 % | $ 6.35 M | ||
|
Alimera Sciences
ALIM
|
18.5 M | - | - | $ 142 M | ||
|
Assertio Holdings
ASRT
|
69 M | $ 15.13 | 8.04 % | $ 96.9 M | ||
|
Canopy Growth Corporation
CGC
|
170 M | $ 0.94 | -2.4 % | $ 101 M | ||
|
Aerie Pharmaceuticals
AERI
|
138 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
10.5 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
13.2 M | - | 0.86 % | $ 117 M | ||
|
Aurora Cannabis
ACB
|
119 M | $ 3.26 | -1.48 % | $ 86.3 M | ||
|
China Pharma Holdings
CPHI
|
1.78 M | $ 0.63 | - | $ 11 M | ||
|
Catalent
CTLT
|
935 M | - | - | $ 11.5 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
181 M | - | - | $ 2.06 B | ||
|
Cronos Group
CRON
|
95.9 M | $ 2.51 | -0.6 % | $ 1.31 B | ||
|
DURECT Corporation
DRRX
|
14.4 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
368 M | $ 7.92 | -1.61 % | $ 406 M | ||
|
Pacira BioSciences
PCRX
|
294 M | $ 22.55 | -0.44 % | $ 1.04 B | ||
|
Endo International plc
ENDP
|
568 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
12.2 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
390 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
58.2 M | - | 2.45 % | $ 38.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
11.1 M | $ 3.01 | -1.31 % | $ 42.3 M | ||
|
Relmada Therapeutics
RLMD
|
32.2 M | $ 6.17 | 5.29 % | $ 244 M | ||
|
Rockwell Medical
RMTI
|
12.1 M | $ 1.05 | 2.94 % | $ 24.5 M | ||
|
Bausch Health Companies
BHC
|
2.92 B | $ 4.98 | -2.35 % | $ 1.82 B | ||
|
Solid Biosciences
SLDB
|
38.9 M | $ 6.9 | -3.22 % | $ 604 M | ||
|
Sundial Growers
SNDL
|
38.4 M | $ 1.35 | -1.1 % | $ 3.37 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.36 M | $ 2.4 | -5.88 % | $ 2.98 M | ||
|
Harrow Health
HROW
|
153 M | $ 34.38 | 1.1 % | $ 1.26 B | ||
|
OptiNose
OPTN
|
79.8 M | - | - | $ 1.08 B | ||
|
Tilray
TLRY
|
165 M | $ 6.33 | -1.86 % | $ 3.91 B | ||
|
Evolus
EOLS
|
221 M | $ 4.48 | -4.27 % | $ 289 M | ||
|
Veru
VERU
|
31.2 M | $ 2.29 | -0.43 % | $ 309 M | ||
|
Eagle Pharmaceuticals
EGRX
|
107 M | - | -39.89 % | $ 27.7 M | ||
|
Viatris
VTRS
|
4.07 B | $ 13.33 | 0.26 % | $ 16 B | ||
|
OrganiGram Holdings
OGI
|
12.8 M | $ 1.36 | - | $ 402 M | ||
|
PetIQ
PETQ
|
196 M | - | 1.64 % | $ 400 M | ||
|
PLx Pharma
PLXP
|
40 M | - | -27.8 % | $ 2.56 M | ||
|
ProPhase Labs
PRPH
|
34.4 M | - | - | $ 5.07 M | ||
|
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | ||
|
Radius Health
RDUS
|
131 M | - | - | $ 1.42 B | ||
|
Lannett Company
LCI
|
81 M | - | 1.15 % | $ 7.11 M | ||
|
SCYNEXIS
SCYX
|
14.4 M | $ 0.9 | 2.51 % | $ 44.9 M | ||
|
TherapeuticsMD
TXMD
|
8.9 M | $ 2.31 | - | $ 24.1 M | ||
|
Organogenesis Holdings
ORGO
|
295 M | $ 2.41 | -2.43 % | $ 317 M | ||
|
Neoleukin Therapeutics
NLTX
|
11.2 M | - | - | $ 193 M | ||
|
Perrigo Company plc
PRGO
|
436 M | $ 9.57 | - | $ 1.33 B | ||
|
Recro Pharma
REPH
|
21 M | - | -4.76 % | $ 65.3 M | ||
|
Tricida
TCDA
|
37.6 M | - | - | $ 3.25 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
14.2 M | - | - | $ 55.5 M |